Ocugen to Participate in Upcoming July Industry Conferences

Ocugen, Inc. announced it will present its innovative modifier gene therapy platform at multiple upcoming conferences in July 2026, including presentations at Piper Sandler Virtual Ophthalmology Day, OIS Retina Innovation Summit, and ASRS annual meeting. The company will showcase Phase 2 OCU410 results and clinical data for inherited retinal diseases including retinitis pigmentosa, Stargardt disease, and geographic atrophy.

07/01/2026, 7:00 AM • GlobeNewswire

3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally

A hantavirus outbreak on a cruise ship sparked a biotech rally, but the article argues investors should avoid jumping in. The hantavirus is less contagious than COVID-19 and unlikely to become a global pandemic, limiting vaccine market potential. Even if it does spread widely, predicting which companies will succeed is nearly impossible, as demonstrated by COVID-19 vaccine developers. Better opportunities exist in established vaccine makers with strong pipelines or broad market index funds.

05/13/2026, 1:15 PM • The Motley Fool

Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells

The longevity biotech market is expanding rapidly, projected to grow from $9.86 billion in 2025 to $29.7 billion by 2034. Multiple companies are advancing cell and gene therapies targeting age-related diseases: Lineage Cell Therapeutics is developing islet therapy for Type 1 diabetes, Ocugen reported 46% lesion reduction in age-related macular degeneration, Vertex is advancing stem cell-derived islet therapy toward regulatory submissions, and Longeveron published positive Phase 2b data for age-related frailty treatment.

04/10/2026, 9:55 AM • Benzinga

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Ocugen announced a webcast on January 15, 2026 to discuss Phase 2 clinical trial data from the OCU410 ArMaDa trial, featuring leading ophthalmologists and company executives. The presentation will cover one-year follow-up data from the first half of patients treated with the modifier gene therapy for blindness diseases.

01/13/2026, 7:00 AM • GlobeNewswire

Gene Therapy for Ocular Rare Disease Market to Exhibit Phenomenal Growth During the Forecast Period (2025–2034) Due to Expanding Pipeline and Clinical Trial Activities | DelveInsight

The gene therapy market for ocular rare diseases is expanding rapidly, with breakthrough viral vector technologies enabling one-time, disease-modifying treatments for inherited retinal disorders. Multiple emerging therapies are expected to transform treatment options for previously untreatable eye conditions.

11/19/2025, 1:00 PM • GlobeNewswire

Why Ocugen Stock Zoomed 12% Higher Today

Ocugen announced a licensing agreement with Kwangdong Pharmaceutical for OCU400, an investigational drug targeting retinitis pigmentosa, potentially earning up to $7.5 million upfront and future royalties of 25% on net sales in South Korea.

09/15/2025, 7:04 PM • The Motley Fool

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Ocugen, a biotechnology company focused on gene therapies for blindness diseases, closed a $20 million registered direct offering with Janus Henderson Investors, selling 20 million shares and warrants at $1.00 per share.

08/12/2025, 3:45 PM • GlobeNewswire

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Ocugen has entered into a securities purchase agreement with Janus Henderson Investors to sell 20 million shares of common stock and warrants at $1.00 per share, expecting to raise approximately $20 million in gross proceeds.

08/08/2025, 5:03 PM • GlobeNewswire

AAV for the Hereditary Retinal Diseases Clinical Trial Pipeline Analysis Demonstrates 70+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight

A comprehensive analysis reveals over 70 companies developing AAV gene therapies for hereditary retinal diseases, offering potential transformative treatments for vision restoration through advanced gene therapy techniques.

08/05/2025, 1:00 PM • GlobeNewswire

Ocugen (OCGN) Shares Slide Following Merger Agreement: What's Going On?

Ocugen's shares are trading lower after the company announced a definitive agreement to merge its subsidiary OrthoCellix with Carisma Therapeutics in an all-stock deal.

06/23/2025, 2:26 PM • Benzinga